Thats correct Jeff this is not a day at the track trying to
Thats correct Jeff this is not a day at the track trying to pick the horses that come in under 1:51 around the track.As we all know horses can not be expected to go full throttle as they will breakdown and never recovery. Stocks take time to ferment like a nice bottle of mancuso 2005.... let it breath..... as it breaths you can breath easier. Stocks take time to develop. The biggest obstacle in all these small caps I have played over the years is 2 items. #1 TOXIC FINANCIN/DILUTION. Most small caps can not overcome the amount of dilution and therby head to .0001 99% of the time. And we passed through #1 it wasn't easy but thanks to a strong knit team here ( yes I said team) we have gone thru the gauntlet. #2. no cash. Well as of q2 we now have 345k in cash and thats before july where we did 4m in revenues ( my guess we get 12.5% or 500K in this case) and if I am accurate we have over 700k in cash currently. If we do 3.5m to 4m we will have yet another 400k to 500k in 30 days in the bank so I would think we will have closer to 1m to 1.2m in cash on hands!!!!
4 to 8 quarters from today is nothing. We not not move for another 2-3 quarters and could be range bound for 6-12 months. The market will be ready when its ready. Whethers its 6 months or 18 months it will come. The company neeeds to do exactly what its doing building a powerhouse in non-narcotic pain approaches. I have a couple of companies that I know of could be a nice compliment to the business we are trying to build. I believe we will become a major player in pain management. There are other companies out there who are using some very exciting scientific approaches in the area of pain management that could be of interest to scrc.
BEFORE AMGEN WAS AMGEN GOING BACK IN 1985 IT HAD NO REVENUES THE SALES NO MONEY NO NOTHING IN 1985. You could have looked at amgem in 1985 and said I am not buying this company there is nothing to it. Well it was approx $5 when I looked at it and I bought it but sold it like a fool because people said I was crazy. I am not suggestiong that scrc will turn into the likes of an Amgn but with some patience more than 1 minute and 51 seconds you may be able to make a lot of $$$$ by exercising some patience. If you elect not to thats your right to do as you please.
As far as .05 stock being sold I am starting to think that people holding that are doing just that. But hey I could be wrong it won't be the first time!
Bottom line if you want true value you know what to do. the decision is up to you.
ScripsAmerica Inc (SCRC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...
Continue Reading
Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...
Continue Reading
Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....
Continue Reading
Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...
Continue Reading
Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...
Continue Reading
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...
Continue Reading
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...
Continue Reading
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
Top 5 Most Recently Viewed Articles
ANSI Electric Vehicles Standards Panel Releases New Report In a significant step towards enhancing the adoption of electric vehicles (EVs) and their infrastructure, the American National Standards Institute (ANSI) has unveiled the May 2025 Gaps Progress Report. This report is integral to understanding the collaborative efforts being made by various stakeholders to bridge...
Continue Reading
Catalyst Accelerator Empowers Startups through Innovative Boot Camp The Catalyst Accelerator is thrilled to unveil a significant opportunity for six emerging tech startups in Oklahoma. This new initiative, the Government Business Boot Camp, is fashioned to equip these talented companies with the insights and tools necessary to succeed in government contracting. In...
Continue Reading
Legal Investigation for Biogen Inc. Stockholders Bragar Eagel & Squire, P.C., a reputable law firm, is currently investigating claims against Biogen Inc. (NASDAQ: BIIB) on behalf of long-term stockholders. This investigation follows the recent filing of a class action complaint aimed at holding the company accountable for alleged misleading statements regarding its...
Continue Reading
The Growing Importance of Data Governance in AI As the landscape of business evolves, the adoption of artificial intelligence (AI) in enterprises has surged, leading to significant transformations in operations, development, and knowledge work. However, this rapid integration of AI solutions has brought about new data risks that traditional technologies often overlook....
Continue Reading
Oracle’s Debt Concerns Illuminate Financial Landscape In a recent analysis, a leading strategist from J.P. Morgan has drawn attention to the substantial debt levels of Oracle Corp. (NYSE: ORCL). Reporting a staggering 500% debt-to-equity ratio, Oracle’s financial commitments appear considerably higher when compared to other companies in the sector. Analysis from J.P....
Continue Reading